Pre-Submission Review for Pharmacology Manuscripts: What Reviewers Expect in 2026
Pharmacology manuscripts need dose-response data, proper controls, in vivo validation, and clear therapeutic relevance. Here is what reviewers at top pharmacology journals expect.
Associate Professor, Clinical Medicine & Public Health
Author context
Specializes in clinical and epidemiological research publishing, with direct experience preparing manuscripts for NEJM, JAMA, BMJ, and The Lancet.
Readiness scan
Find out if this manuscript is ready to submit.
Run the Free Readiness Scan before you submit. Catch the issues editors reject on first read.
How to use this page well
These pages work best when they behave like tools, not essays. Use the quick structure first, then apply it to the exact journal and manuscript situation.
Question | What to do |
|---|---|
Use this page for | Building a point-by-point response that is easy for reviewers and editors to trust. |
Start with | State the reviewer concern clearly, then pair each response with the exact evidence or revision. |
Common mistake | Sounding defensive or abstract instead of specific about what changed. |
Best next step | Turn the response into a visible checklist or matrix before you finalize the letter. |
Decision cue: Pharmacology sits at the intersection of chemistry, biology, and medicine. Reviewers expect manuscripts to demonstrate not just that a compound is active but that the activity is specific, reproducible, dose-dependent, and therapeutically relevant. A paper showing that compound X inhibits enzyme Y at 10 micromolar is not pharmacology. A paper showing dose-dependent inhibition with selectivity data, in vivo efficacy, pharmacokinetic characterization, and a clear therapeutic hypothesis is pharmacology worth publishing.
Check your pharmacology manuscript readiness in 60 seconds with the free scan.
What pharmacology reviewers check first
Dose-response relationships
Pharmacology is fundamentally about dose-response. Reviewers expect:
- complete dose-response curves (not single-concentration tests)
- IC50, EC50, or Ki values calculated from the curves
- Hill coefficients or slope factors reported
- appropriate curve-fitting methods described
- adequate number of concentrations tested (minimum 6 to 8 for a meaningful curve)
Selectivity and specificity
A compound that hits everything is not a drug candidate. Reviewers expect:
- selectivity testing against related targets (kinase panels, receptor panels, etc.)
- counterscreens ruling out nonspecific mechanisms (aggregation, membrane disruption, assay interference)
- PAINS analysis for medicinal chemistry papers (pan-assay interference compounds)
- appropriate negative controls (structurally similar inactive compounds)
In vivo validation
For papers claiming therapeutic potential, reviewers expect:
- pharmacokinetic data (Cmax, t1/2, AUC, oral bioavailability)
- efficacy in a disease-relevant animal model
- dose selection justified by PK data (not arbitrary)
- toxicity assessment at efficacious doses
- appropriate vehicle and route of administration controls
Reproducibility and statistical rigor
- biological replicates (not just technical replicates)
- sample sizes justified for the expected effect
- blinding where appropriate (especially for in vivo studies)
- statistical tests matched to the data type
- ARRIVE 2.0 guidelines followed for animal experiments
Common pharmacology desk rejection triggers
The most common reasons pharmacology manuscripts are rejected at top journals:
- Single-concentration testing. Showing activity at one concentration proves nothing about pharmacology. Reviewers expect full dose-response curves with calculated potency values. A paper that says "compound X inhibited enzyme Y at 10 micromolar" without a dose-response curve will be returned immediately.
- No selectivity data. A compound that hits everything is not a therapeutic lead. If the paper claims therapeutic potential without demonstrating selectivity against off-targets, reviewers will question whether the observed effects are specific or artifacts.
- In vivo efficacy without PK. Dosing an animal without knowing the pharmacokinetics is not pharmacology. If the paper shows in vivo efficacy, reviewers expect to see at least basic PK data (plasma levels, half-life) showing that the compound reaches the target at relevant concentrations.
- PAINS compounds not flagged. Pan-assay interference compounds (PAINS) are structural motifs known to interfere with common assay formats. If the compound contains a PAINS alert and the paper does not address it, reviewers familiar with medicinal chemistry will flag the omission.
- Overclaimed therapeutic potential. In vitro data alone does not demonstrate therapeutic utility. Claims about "potential new treatment for disease X" based on enzyme inhibition in a cell-free assay are overclaimed.
The pharmacology pre-submission checklist
For in vitro pharmacology
- dose-response curves with IC50/EC50/Ki for all key compounds
- selectivity data against related targets
- counterscreens for assay artifacts
- mechanism of action data (binding kinetics, reversibility, competitive vs noncompetitive)
- appropriate positive and negative controls in every assay
For in vivo pharmacology
- PK data supporting dose selection
- efficacy in a disease-relevant model (not just a convenient one)
- dose-response in vivo (not just one dose)
- appropriate vehicle controls
- toxicity assessment
- ARRIVE 2.0 compliance
For all pharmacology manuscripts
- compound identity confirmed (HPLC purity, NMR, mass spec)
- compound stability assessed in assay conditions
- data deposited where applicable
- statistical methods described and appropriate
- conclusions proportional to the evidence (in vitro data alone does not prove therapeutic utility)
Where pre-submission review helps in pharmacology
The Manusights free readiness scan evaluates methodology and journal fit in about 60 seconds. For pharmacology manuscripts, citation verification catches missing references to competing compounds or recently published drug targets.
The $29 AI Diagnostic provides figure-level feedback, which is important for dose-response curves and pharmacology data presentations. For high-stakes submissions, Manusights Expert Review connects you with reviewers experienced in pharmacology publishing.
On this page
Reference library
Use the core publishing datasets alongside this guide
This article answers one part of the publishing decision. The reference library covers the recurring questions that usually come next: how selective journals are, how long review takes, and what the submission requirements look like across journals.
Dataset / reference guide
Peer Review Timelines by Journal
Reference-grade journal timeline data that authors, labs, and writing centers can cite when discussing realistic review timing.
Dataset / benchmark
Biomedical Journal Acceptance Rates
A field-organized acceptance-rate guide that works as a neutral benchmark when authors are deciding how selective to target.
Reference table
Journal Submission Specs
A high-utility submission table covering word limits, figure caps, reference limits, and formatting expectations.
Final step
Find out if this manuscript is ready to submit.
Run the Free Readiness Scan. See score, top issues, and journal-fit signals before you submit.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Need deeper scientific feedback? See Expert Review Options
Where to go next
Supporting reads
Conversion step
Find out if this manuscript is ready to submit.
Anthropic Privacy Partner. Zero-retention manuscript processing.